EPZM Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 18 Posts
1 2
Notable Insider Buys: Continental Resources, Fox, Groupon And More
Article By: Benzinga Saturday, June 27, 2020 7:24 PM EDT
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. So insider buying can be an encouraging signal for potential investors.
In this article: CLR, ED, CATM, RPRX, GRPN, WSBC, EPZM, FOX, VST
Read
The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke, And Ultragenyx
Article By: Benzinga Sunday, June 14, 2020 3:13 PM EDT
Biotech stocks came under pressure along with the broader market in the week that ended June 12, as a worsening pandemic situation and its impact on the economy led to an across-the-board sell-off in the global markets.
In this article: MRK, EVOK, RARE, EPZM Also: AZN, GILD, BMY, SNY, RPRX, CELG, PRQR, NBRV, CBIO, UROV, CNTG
Read
Wall Street's Top Weekend Stories, Sunday Dec. 6th
Article By: The Fly Sunday, January 6, 2019 9:10 PM EDT
Stocks rebounded following a positive jobs report, Powell's comments, and more.
In this article: AZN, GME, MAR, FTNT, IRWD, INTC, NFLX, EPZM
Read
Epizyme Announces Closing Of Public Offering Of Common Stock
Article By: NASDAQ GlobeNewswire Tuesday, September 19, 2017 10:19 AM EDT
Epizyme, Inc., today announced the closing of its public offering of 10,557,000 shares of its common stock at a price of $15.25 per share, before underwriting discounts.
In this article: EPZM
Read
Epizyme Announces Pricing Of Public Offering Of Common Stock
Article By: NASDAQ GlobeNewswire Thursday, September 14, 2017 1:24 PM EDT
Epizyme, Inc., today announced the pricing of an underwritten public offering of 9,180,000 shares of its common stock at a price of $15.25 per share, before underwriting discounts.
In this article: EPZM
Read
Biotech Fades After ASCO Abstract Rally
Article By: Rod Raynovich Friday, May 26, 2017 6:29 PM EDT
Biotechs faded today now that the rush of oncology drug news cooled down. Today was dominated by the “red screen” with profit taking mainly in smaller caps and momentum driven oncology stocks.
In this article: MRK, ALNY, ALXN, BMRN, INCY, CELG, CLVS, VRTX, ZIOP, JUNO, PBYI, EPZM, GLYC, KITE, TSRO
Read
ASCO Abstracts Week: Biotech Trends And Hot Stocks
Article By: Rod Raynovich Monday, May 22, 2017 10:58 PM EDT
Today Amgen was down over 2 % on news that its osteoporosis treatment Evenity is unlikely to win FDA approval this year because of a safety risk. Radius Health was up over 6% to $37.30 as their rival drug Tymlos was approved in April.
In this article: MRK, ALNY, IBB, INCY, REGN, AMGN, CLVS, VRTX, FBT, XBI, PUMA, JUNO, EPZM, GLYC, KITE, BLUE, RDUS
Read
5 Top-Ranked Stocks To Buy Before Earnings Release In April
Article By: Zacks Investment Research Wednesday, April 6, 2016 3:14 PM EDT
In spite of all the hiccups in Q1, we have cherry picked stocks with the help of our screening methodology that have been able to bear the turmoil.
In this article: CPN, CX, EIX, WLB, EPZM Also: AA
Read
Morning Call - January 6, 2016
Article By: Jim Van Meerten Wednesday, January 6, 2016 4:26 PM EDT
Apple fell nearly 3% in pe-market trading after the Nikkei Asian Review reported that Apple would reduce Q1 output of its latest iPhones by about 30%.
In this article: AN, FCX, MON, MSM, PXD, RPM, ACAD, NUVA, AAPL, COST, GILD, LNDC, ORCL, SIRI, SONC, EPZM, CNAT
Read
E Epizyme Achieves Extension Of Celgene Collaboration
Article By: Terry Chrisomalis Thursday, July 9, 2015 1:11 PM EDT
Epizyme gets a three-year extension on its research collaboration with Celgene.
In this article: EPZM, CELG
Read
Biotech Stocks Lose Momentum With Greece Crisis; Blockbuster Immunotherapy Deal
Article By: Rod Raynovich Monday, June 29, 2015 9:56 PM EDT
The biotech sector is usually immune to macro events but today the crisis in Greece gave investors an excuse to take profits. Many biotech stocks and ETFs were down over 3% faring worse than the NASDAQ down 2.4%.
In this article: ADRO, BLUE, CELG, CLDX, EPZM, IBB, ICPT, JUNO, KITE, QQQ, SRPT, XBI
Read
E Shares Of Epizyme Are Up 26.75% After Reporting Positive Results In Non-Hodgkin Lymphoma Patients
Article By: Terry Chrisomalis Monday, June 22, 2015 2:57 PM EDT
Epizyme reported positive efficacy results in a phase 1 trial in patients with Non-Hodgkin Lymphoma. Shares of Epizyme (EPZM) are up 26.75% today.
In this article: EPZM
Read
Monday Morning Pre-Market Insights: AMD, ZIOP, EPZM, BLRX
Article By: TipRanks Monday, June 22, 2015 8:45 AM EDT
Monday Morning Pre-Market Insights: Advanced Micro Devices, Inc., ZIOPHARM Oncology, Inc., Epizyme, Inc. and BioLineRx, Ltd.
In this article: AMD, BLRX, EPZM, ZIOP
Read
Biotech Stocks Hit By Profit Taking-More Volatility Lies Ahead
Article By: Rod Raynovich Tuesday, December 2, 2014 5:00 AM EDT
Don’t blame the consumer and retail sales for the sell-off. Investors have done very well this year with simple indexing.
In this article: CLDX, SGEN, AMGN, BIIB, GILD, XLV, EPZM, GLYC, AGIO
Read
The Dow And The S&P Both Hit New Intraday Highs
Article By: BioMedReports Thursday, November 6, 2014 5:59 PM EDT
U.S. stocks were mixed in a quiet session Thursday as rising hopes about more stimulus in Europe were tempered by a continuing decline in oil prices.
In this article: AKRX, ALXA, EDAP, EPZM, SRPT
Read
ASH 2014 Abstracts Are About To Hit: Here Are Some Of The Names To Follow
Article By: Jake King Thursday, November 6, 2014 8:30 AM EDT
One of the biggest events in healthcare annually, the American Society of Hematology’s annual meeting (56th!) begins on December 6, but abstracts from the conference will be released this morning. Here's a primer on the stocks to watch.
In this article: BMY, MRK, GERN, TGTX, EPZM, AGIO, KPTI, KITE, BLUE
Read
1 to 16 of 18 Posts
1 2